References
- Marth T, Moos V, Müller C, et al. Tropheryma whipplei infection and Whipple's disease. Lancet Infect Dis. 2016;16:e13–e22.
- Keinath RD, Merrell DE, Vlietstra R, et al. Antibiotic treatment and relapse in Whipple's disease. Long-term follow-up of 88 patients. Gastroenterology. 1985;88:1867–1873.
- Feurle GE, Junga NS, Marth T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. Gastroenterology. 2010;138:478–486.
- Lagier JC, Fenollar F, Lepidi H, et al. Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple's disease. J Antimicrob Chemother. 2010;65:2005–2012.
- Moos V, Schmidt C, Geelhaar A, et al. Impaired immune functions of monocytes and macrophages in Whipple's disease. Gastroenterology. 2010;138:210–220.
- Martinetti M, Biagi F, Badulli C, et al. The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple's disease. Gastroenterology. 2009;136:2289–2294.
- Biagi F, Badulli C, Feurle GE, et al. Cytokine genetic profile in Whipple's disease. Eur J Clin Microbiol Infect Dis. 2012;31:3145–3150.
- Schöniger-Hekele M, Petermann D, Weber B, et al. Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol. 2007;73:2033–2035.
- Zinkernagel AS, Gmür R, Fenner L, et al. Marginal and subgingival plaque–a natural habitat of Tropheryma whipplei?. Infection. 2003;31:86–91.
- Fenollar F, Keita AK, Buffet S, et al. Intrafamilial circulation of Tropheryma whipplei, France. Emerg Infect Dis. 2012;18:949–955.
- Lagier JC, Fenollar F, Lepidi H, et al. Evidence of lifetime susceptibility to Tropheryma whipplei in patients with Whipple's disease. J Antimicrob Chemother. 2011;66:1188–1189.
- Mbeye NM, ter Kuile FO, Davies MA, et al. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2014;19:1057–1067.
- Bakkali N, Fenollar F, Biswas S, et al. Acquired resistance to trimethoprim-sulfamethoxazole during Whipple disease and expression of the causative target gene. J Infect Dis. 2008;198:101–108.
- Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–68.
- Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011;183:1851–1858.
- Chamber HF. Protein synthesis inhibitors and miscellaneous antibacterial agents (Chapter 46). In: Brunton LL, editor. Goodman and Gilman’s, the pharmacological basis of therapeutics. 11th ed. New York: Mc Graw-Hill; 2006. p. 1173–1202.
- Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58:256–265.
- Dubourg G, Lagier JC, Armstrong N, et al. Concentrations of doxycycline in cerebrospinal fluid in Whipple's disease. Int J Antimicrob Agents. 2015;45:677–678.
- Dersch R, Freitag MH, Schmidt S, et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis – a systematic review. Eur J Neurol. 2015;22:1249–1259.
- Kang-Birken SL, Castel U, Prichard JG. Oral doxycycline for treatment of neurosyphilis in two patients infected with human immunodeficiency virus. Pharmacotherapy. 2010;30:119e–122e.
- Gaillard T, Madamet M, Pradines B. Tetracyclines in malaria. Malar J. 2015;14:445.